Disease/Infection News

RSS

Researchers identify several novel SARS-CoV-2 inhibitors

Researchers in London, UK, have identified several compounds with SARS-CoV-2 inhibiting properties, that potentially may be developed into antiviral solutions in the future.

9 Apr 2021

Researchers discover a new monoclonal antibody that is effective against SARS-CoV-2 variants

A new monoclonal antibody targets a particular region of the RBD on the SARS-CoV-2. This region is usually not accessible to immune cells, which may be why it has broad neutralizing capabilities.

9 Apr 2021

How has the COVID-19 pandemic affected sleep patterns for many US citizens?

A team of scientists recently conducted an online survey to examine the changes in sleep duration among adult US citizens during the COVID-19 pandemic.

9 Apr 2021

Antipsychotics could have a protective impact against SARS-CoV-2

Two studies led by the Mental Health Unit of the Virgen del Rocio University Hospital and involving researchers from the US conclude that antipsychotic drugs could have a protective effect against SARS-CoV-2. For this reason, patients treated with these drugs have a lower risk of becoming infected or suffer a milder form of the disease if they do become infected.

9 Apr 2021

Study finds no evidence of SARS-CoV2 transmission by breast milk

Some studies have reported the detection of SARS-CoV-2 RNA in breast milk from women who were recently infected with the virus. A new study explores the relationship between viral RNA and infectious virus to clarify the occurrence of vertical transmission through breast milk.

9 Apr 2021

Does natural infection with SARS-CoV-2 offer more protection than a vaccine against new variants?

A new study demonstrates that vaccines may be less effective at countering the newer SARS-CoV-2 variants compared to natural infection.

9 Apr 2021

Serum and breast milk SARS-CoV-2 antibodies correlated in vaccinated mothers

A new study shows the correlation between serum levels of antibodies to SARS-CoV-2 and levels in breast milk following the vaccination of lactating women with a vaccine based on mRNA technology.

9 Apr 2021

Researchers reveal blood clot risk and anticoagulation benefits in discharged COVID-19 patients

In the largest study of its kind, Feinstein Institutes for Medical Research and Northwell COVID-19 Research Consortium researchers reveal blood clot risk and anticoagulation benefits in hospitalized coronavirus disease 2019 (COVID-19) patients who have been recently discharged from the hospital.

9 Apr 2021

Novel protein transport system mediates toxin secretion by tuberculosis pathogen

Six years ago, Michael Niederweis, Ph.D., described the first toxin ever found for the deadly pathogen Mycobacterium tuberculosis.

9 Apr 2021

Probabilistic model can help analyze patient trajectories during COVID-19 pandemic

As SARS-CoV-2 continues to spread in France, a thorough characterization of hospital care needs and of the trajectories of hospital patients, as well as how they have changed over time, is essential to support planning.

9 Apr 2021

Beth Israel Lahey Health to develop new strategies to distribute COVID-19 vaccines

When the first COVID-19 vaccines were approved for emergency use in December 2020, healthcare systems across the Unites States needed to rapidly design and implement their own approaches to distribute COVID-19 vaccines equitably and efficiently

9 Apr 2021

Novel PF74 molecule effectively targets HIV capsid protein

Of all known small molecules targeting human immunodeficiency virus (HIV) capsid protein (CA), PF74 represents by far the best characterized chemotype, due to its ability to confer antiviral phenotypes in both early and late phases of viral replication.

9 Apr 2021

Oxford-AstraZeneca COVID vaccine induces cell spikes similar to SARS-CoV-2's

Scientists from the University of Oxford and the University of Southampton report in the journal ACS Central Science that cells infected with the ChAdOx1 vaccine produce spike proteins on the cells similar to those produced by natural SARS-CoV-2 infection.

9 Apr 2021

Effective response to HIV and COVID-19 pandemics requires accelerated research

The COVID-19 pandemic is affecting people with or at risk for HIV both indirectly, by interfering with HIV treatment and prevention services, and directly, by threatening individual health.

9 Apr 2021

Asymptomatic SARS-CoV-2 individuals with blood group AB at highest risk

Scientists worldwide are conducting extensive research to understand the nature of the virus, its transmission kinetics, etc. They have found a strong correlation between the ABO blood group and SARS-CoV-2 regarding its morbidity and mortality.

9 Apr 2021

Statins improve 28-day mortality in hospitalized COVID-19 patients

Now, researchers at Harvard Medical School showed that statin use reduced 28-day mortality in patients hospitalized with COVID-19. Both the new initiation of statins and continuing statin therapy reduced the risk of mortality.

8 Apr 2021

High SARS-CoV-2 attack rates linked to singing events

Now, a team of researchers from the Netherlands and Sweden demonstrates that airborne spread via infectious droplets or aerosols over longer distances of more than 1.5 meters due to singing is possible during singing events.

8 Apr 2021

More new SARS-CoV-2 variants are highly likely

In a recent report posted to the bioRxiv preprint server, researchers from the United Kingdom and Uganda reveal unique protein features of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) relative to other representatives of Sarbecoviruses.

8 Apr 2021

Purdue researchers use malaria expertise to track COVID-19 in Indiana

Scientists have been using genetics to track diseases for decades. Now, a team at Purdue University that typically tracks malaria spread in Southern and Central Africa is using its expertise to track COVID-19 in Indiana.

8 Apr 2021

Phase 2 clinical trial launched in Thailand to evaluate IL-15 agonist as therapy to reduce HIV reservoir

The U.S. Military HIV Research Program (MHRP) at the Walter Reed Army Institute of Research last week launched a Phase 2 clinical trial in Thailand to evaluate an interleukin-15 (IL-15) superagonist, ImmunityBio's Anktiva (also called N-803), administered during acute HIV infection as an experimental therapy to target establishment of the HIV reservoir at a very early stage.

8 Apr 2021